Tirzepatide improves patient-reported outcomes and objective assessments in adults with moderate-to-severe OSA and obesity, with greater improvements in those with worse baseline fatigue, sleepiness, or sleep quality.
In two 52-week randomized placebo-controlled trials (SURMOUNT-OSA), tirzepatide (10/15 mg) led to greater improvements in patient-reported outcomes (e.g., fatigue, sleepiness, sleep quality) and objective measures (AHI, weight, OSA remission) compared to placebo. Participants with worse baseline symptoms showed larger improvements on related PROMs, while objective improvements were similar across severity subgroups.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Tirzepatide improves patient-reported outcomes and objective assessments in adults with moderate-to-severe OSA and obesity, with greater improvements in those with worse baseline fatigue, sleepiness, or sleep quality. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Tirzepatide improves patient-reported outcomes and objective assessments in adults with moderate-to-severe OSA and obesity, with greater improvements in those with worse baseline fatigue, sleepiness, or sleep quality.
This conclusion is most relevant to: Adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, either not using PAP (Study 1) or using PAP (Study 2).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses. (Sleep, 2026) —
How It Works
The proposed biological pathway:
- ▸Tirzepatide activates GIP and GLP-1 receptors
- ▸Reduces appetite and promotes weight loss
- ▸Weight loss reduces upper airway collapsibility and improves OSA severity
- ▸Result: Improved patient-reported outcomes and objective OSA measures
Who Might Benefit
Evidence fit by population:
- ▸Adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, either not using PAP (Study 1) or using PAP (Study 2)
Recommended Dose
10 mg or 15 mg weekly
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Post-hoc analyses are exploratory and not pre-specified, increasing risk of bias
- ▸Subgroup definitions based on self-reported baseline severity may be subjective and not validated
Frequently Asked Questions
What is tirzepatide?▼
Tirzepatide is a dual GIP and GLP-1 receptor agonist used for weight management and type 2 diabetes, and in this study, it was tested for obstructive sleep apnea.
How much did tirzepatide improve sleep-related outcomes?▼
Improvements varied by subgroup; for example, in fatigued participants, the SF-36v2 Vitality score improved by 8.5 points more than placebo, and in sleepy participants, PROMIS Sleep-Related Impairment improved by 7.1 points more than placebo.
Did tirzepatide work for all participants regardless of baseline severity?▼
Objective improvements (e.g., AHI reduction, weight loss) were similar across all severity subgroups, but patient-reported improvements were larger in those with worse baseline fatigue, sleepiness, or sleep quality.
What were the study durations?▼
Both studies lasted 52 weeks.
References
- 1.Kanu C, Shinde S, Falcon B, Bednarik J, Xie CC, Trice K, Weaver T. “Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses..” Sleep, 2026. PMID: 42412744 DOI: 10.1093/sleep/zsag184